A multimodality approach to assessing Factor I genetic variants in atypical hemolytic uremic syndrome by Java, Anuja et al.
Washington University School of Medicine 
Digital Commons@Becker 
Open Access Publications 
7-1-2019 
A multimodality approach to assessing Factor I genetic variants in 
atypical hemolytic uremic syndrome 
Anuja Java 
Nicola Pozzi 
Latisha D Love-Gregory 
Jonathan W Heusel 
Yun Ju Sung 
See next page for additional authors 
Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs 
Authors 
Anuja Java, Nicola Pozzi, Latisha D Love-Gregory, Jonathan W Heusel, Yun Ju Sung, Zheng Hu, Paula 
Bertram, M Kathryn Liszewski, Laura M Cline, Zhen Ren, and John P Atkinson 
A Multimodality Approach to Assessing
Factor I Genetic Variants in Atypical
Hemolytic Uremic Syndrome
Anuja Java1, Nicola Pozzi2, Latisha D. Love-Gregory3, Jonathan W. Heusel3, Yun Ju Sung4,
Zheng Hu1, Paula Bertram5, M. Kathryn Liszewski5, Laura M. Cline5, Zhen Ren6 and
John P. Atkinson5
1Department of Medicine, Division of Nephrology, Washington University School of Medicine in St. Louis, St. Louis, Missouri,
USA; 2Department of Biochemistry and Molecular Biology, Edward A. Doisy Research Center, Saint Louis University School of
Medicine, St. Louis, Missouri, USA; 3Genomic and Pathology Services, Department of Pathology and Immunology, Wash-
ington University School of Medicine in St. Louis, St. Louis, Missouri, USA; 4Department of Medicine, Division of Biostatistics,
Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA; 5Department of Medicine, Division of
Rheumatology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA; and 6Department of Medicine,
Division of Allergy and Immunology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA
Correspondence: Anuja Java, 660 S Euclid Avenue, Campus Box 8045, St. Louis, MO 63110, USA. E-mail: ajava@wustl.edu
Received 11 March 2019; revised 25 March 2019; accepted 1 April 2019; published online 9 April 2019
Kidney Int Rep (2019) 4, 1007–1017; https://doi.org/10.1016/j.ekir.2019.04.003
ª 2019 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A typical hemolytic uremic syndrome (aHUS) is arare thrombotic microangiopathy (TMA) charac-
terized by the triad of microangiopathic hemolytic
anemia, thrombocytopenia, and acute kidney injury
(AKI).1,S1–S5 The disease features overactivity of the
alternative pathway of the complement system, most
often arising from loss-of-function mutations in regula-
tors (Factor H, Factor I, and membrane cofactor pro-
tein).S4–S7 Less frequently, a gain-of-function mutation
in 1 of 2 activators (C3, Factor B) is identified.S8–S10
Approximately 60% of patients with aHUS carry a
rare variant in one of the complement proteins.
However, <50% of these rare variants have a known
functional consequence or one that is readily predicted
from the DNA sequence alteration (such as nonsense,
splice-site, or frame-shift mutations).1,S4 Most of the
clinically identified variants have not been functionally
characterized. Instead, computational prediction algo-
rithms are utilized to predict the potential impact of
these variants on the mature protein, taking into
consideration the following: (i) evolutionary conserva-
tion of an amino acid or nucleotide; (ii) location and
context within the protein sequence; (iii) biochemical
consequence of the amino acid substitution, and, in
some cases, (iv) topology of a previously solved struc-
tural domain or subdomain. Based on these criteria, most
variants are reported as variants of uncertain clinical
significance (VUSs). The presence of such rare variants is
particularly vexing for clinical management.
Genetic variants in Factor I (FI) have been reported
in 5%–15% of patients with aHUS.2,S4 The likely
clinical outcome of patients with an FI mutation is
dismal, and the risk of recurrence after kidney trans-
plantation is high.3,S11–S15 FI is a plasma glycoprotein
regulator of the alternative pathway of the complement
system (Figure 1).4,S16–S18 It is a 2-chain 88-kDa serine
protease synthesized predominantly by the liver. FI
regulates complement activation by inactivating C3b
and C4b through proteolytic cleavage (i.e., cofactor ac-
tivity) in the presence of one of its “cofactor proteins”—
Factor H (FH), membrane cofactor protein (MCP; CD46),
C4b-binding protein (C4BP), or complement receptor 1
(CR1; CD35).
Our study hypothesized that the clinical presentation
and pathology of aHUS can be better understood and
treated by examining critical clinical information, and
by profiling the functional repertoire along with
structurally modeling genetic variants. This approach
integrates information derived from several types of
analyses in order to create a more informed model. The
strategy described in this report thus provides a model
for how to characterize these rare variants clinically
based upon functional evidence, which is one of the
interpretive categories of the American College of
Medical Genetics (ACMG)5 guidelines for variant in-
terpretations related to pathogenicity. This strategy
may be useful for guiding more-appropriate medical
therapeutic decisions and generating further insights
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Figure 1. Structure and function of Factor I (FI). Cartoon schematic of FI. White stars represent the location of the variants (a). Crystal structure
of FI (generated using Pymol). Symbols indicate the following: purple circles ¼ variant sites; blue circles ¼ calcium atoms; yellow circles ¼
serine protease (SP) site; light-blue hexagons ¼ N-glycosylation sites. Thick arrow-shaped structures in the various domains are(continued)
RESEARCH LETTERS
1008 Kidney International Reports (2019) 4, 1004–1018
relative to the pathogenic mechanisms underlying
aHUS.
RESULTS
This report describes 5 patients in whom aHUS was
considered as a possible diagnosis. Genetic testing
revealed a variant in FI (Table 1). These patients were
referred to us for assistance in clinical decision-making
relative to therapeutic options for renal transplant and/
or targeted therapy using a humanized monoclonal anti-
body that blocks C5 activity (eculizumab).6,S19–S21 In or-
der to obtain a more comprehensive assessment of each
patient’s risk, we wanted to evaluate their clinical history
and genetic data in relation to a functional assessment of
each variant. Our hypothesis was that the additional re-
sults would provide critical information for preparing a
more rational assessment for individualized therapeutic
decisions for each patient. Therefore, we produced re-
combinant proteins, assessed regulatory function
(cofactor activity), and performed structural modeling of
each variant protein (see Supplementary Methods,
STROBE Statement, and Figure 27).
Case 1
This 22-year-old Caucasian male developed end-stage
renal disease at the age of 3 years, thought to be sec-
ondary to Escherichia coli–triggered HUS. In 2006, he
underwent a renal transplant at age 11 years. In 2007, he
developed renal failure due to Banff 1B acute cellular
rejection and returned to dialysis in 2009. He was eval-
uated for a second renal transplant in 2014. Given his
history of HUS, genetic testing was performed, which
showed a missense variant (p.R406H) in FI. The patient
received eculizumab for 1 year after his second transplant
in May 2015. In April 2017, an allograft biopsy for
worsening renal function again revealed Banff 1B acute
cellular rejection, in addition to antibody-mediated
rejection. As of this writing, he is undergoing evalua-
tion for a third renal transplant.
Genetic Analysis
The patient’s heterozygous variant is within the serine
protease domain and occurs at an amino acid position that
is not conserved. This variant has been reported in pa-
tients with age-related macular degeneration,S22 and at
the time the variant was identified in this patient, the
frequency in the general population was reported at
0.12%. Due to the availability of larger cohorts in gno-
mAD, this variant is now reported to occur at an overall
frequency of 1.6% (minor allele frequency: Asians,
2.4%–4.3%; Europeans, 0.1%–2.4%; Africans and
Latinos, <1%). Several in silico models (SIFT, PolyPhen2,
Mutation Assessor, Condel) predict this variant to be
benign; taken together, the clinical interpretation re-
ported for this variant was “likely benign.”
Antigenic Analysis
The secretion of the recombinantly produced variant
protein in the supernatant (determined by enzyme-linked
=
Figure 1. (continued) beta-pleated sheets. The dotted beige line in the linker represents a structure that is not visible in the crystal structure,
and its location is therefore hypothetical (b). C3b binding and cofactor activity. FI, in the presence of a cofactor protein (factor H [FH], membrane
cofactor protein [MCP; CD46], or complement receptor 1 [CR1; CD35]), cleaves the aˈ chain of C3b to obtain a41 and a43 (liberating C3f, a 2-kDa
fragment), forming iC3b. Next, CR1 achieves further cleavage of iC3b to C3c and C3dg (c,d). Arg, arginine; Asp, aspartic acid; C, carboxyl-
terminus; FIMAC, FI membrane attack complex; Ile, isoleucine; LDLR1, low-density lipoprotein receptor class 1; LDLR2, low-density lipoprotein
receptor class 2; N, amino-terminus; Pro, proline; SRCR, scavenger receptor cysteine-rich.
Table 1. Summary of clinical data of patients with Factor I variants
Patient Variant Age/sex Age of onset Outcomes Transplant Treatments aHUS-risk SNPs
Additional serum
complement levels
1 R406H 22 yr/M 3 yr ESRD Two failed transplants Eculizumab x 1 year after
second transplant
None reported C3:72 mg/dl
C4: 15 mg/dl
2 I306V 17 yr/F 17 yr CR None Plasmapheresis, eculizumab,
Cellcept, and Prednisone
FH: V62I, H402Y
FI: T300A
FB: R32Q, R32W
C3: 45 mg/dl
C4: 6 mg/dl
3 P553S 20 yr/F 19 yr ESRD Awaiting transplant Supportive treatment FH: V62I, H402Y
FI: T300A
C3: R102G, P314L
C3: 103 mg/dl
C4: 24.9 mg/dl
4 D403N 57 yr/M 57 yr CR None Eculizumab x 6 years FH: H402Y
FI: T300A
C3: R102G, P314L
FB: G252S
C3: 95 mg/dl
C4: 34 mg/dl
CH50: 50 U/ml
5 I370N 24 yr/M 19 yr CKD None Supportive treatment FH: V62I, H402Y, E936D
FI: T300A
C3: R102G, P314L
Not available
aHUS, atypical hemolytic uremic syndrome; CKD, chronic kidney disease; CR, complete remission; ESRD, end-stage renal disease; F, female; FB, Factor B; FH, Factor H; FI, Factor I; M,
male; SNP, single-nucleotide polymorphisms.
For patients 1, 2, and 3, the reference range for C3 is 82–167 mg/dl; the reference range for C4 is 10–40 mg/dl. For patient 4, the reference range for C3 is 98–201 mg/dl; the reference
range for C4 is 18–56 mg/dl; and the reference range for CH50 is 30–75 U/ml.
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immunosorbent assay) was comparable to wild type (WT,
2.3  0.75 mg/ml; R406H, 2.1  0.97 mg/ml). The serum
FI antigenic level in this patient was normal: 31 mg/ml
(reference range for the outside laboratory: 24–49 mg/ml).
Functional Analysis
This FI variant had defective proteolytic activity with
FH and CR1 as cofactor proteins, as evidenced by a
decreased rate of cleavage of the aʹ chain of C3b and
thereby reduced generation of the a1 fragment
compared to WT (Figure 3). P values for the difference
in functional activity between the WT and variant
were statistically significant. No defect was observed
with MCP as the cofactor protein.
Structural Analysis
The side chain of R406 in FI forms a salt bridge with
the carboxyl group of E123 of FH7,S23 (Figure 2). This
interaction stabilizes the FI–FH binding interface.
Residue E123 is a unique signature of FH and is lacking
in MCP, possibly accounting for the fact that the
R406H mutation impaired FH- but not MCP-mediated
cofactor activity. The effect of the mutation on CR1
cofactor activity is more difficult to interpret because
residue E123 is also absent in CR1, being replaced by a
histidine. However, given that a histidine residue can
be protonated under physiological values of pH and
ionic strength conditions,S24 a histidine–arginine like-
charged ion pair is expected to occur at the FI–CR1
binding interface.
Implications
Although this variant was synthesized normally, it had
a reduced rate of C3b cleavage by FH and CR1
compared to WT FI. This variant is therefore “func-
tionally impaired.” However, taken together with the
frequency of the p.R406H variant, which is more
common than would be expected based on the preva-
lence of aHUS, lack of consistency between in silico
tools and now our data supporting pathogenicity, this
variant is being reclassified as a VUS according to
ACMG guidelines. Of note, although glomerular
endothelial cellsS25 do not express CR1 in the resting
state, there is evidence that hypoxia or inflammatory
mediators may induce the expression of this CR1 on
endothelial cells. This phenomenon could therefore be
of significance during disease states such as aHUS. We
also know that aHUS is a disease with incomplete
penetrance and that the penetrance is age-related, be-
ing reported as being as high as 65% by age 70 years
for individuals carrying a single genetic mutation.S26
Therefore, although this patient did not develop
TMA, given his clinical course with end-stage renal
disease secondary to HUS, 2 allograft rejections, and
our newly derived data, we believe that the patient is
at risk of developing a TMA and/or an accelerated
Figure 2. Mapping of the Factor I (FI) variants on the surface of C3b in a complex with FI and Factor H (FH; complement control repeats 1–4 and
19–20]. Color coding is as follows: C3b, gray; FH, cyan; serine protease, red; FI membrane attack complex, blue; linker, beige; low-density li-
poprotein receptor (LDLR) class 1, yellow; LDLR class 2, orange; scavenger receptor cysteine-rich, green. FI domains are color coded to match
those in Figure 1. Refer to the text for further explanation of the structural evaluation for each variant. D, aspartic acid; H, histidine; I, isoleucine;
N, asparagine; P, proline; R, arginine; S, serine; V, valine. Adapted with permission from Forneris F, Wu J, Xue X, et al. Regulators of complement
activity mediate inhibitory mechanisms through a common C3b-binding mode. EMBO J. 2016;35:1133–1149.7 Copyright ª 2016 The Authors.
Published under the terms of the CC BY-NC-ND 4.0 license.
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antibody-mediated rejection. Although future studies
will affect the decision on how long to continue
treatment, we would recommend that he receive ecu-
lizumab at the time of his third transplant and remain
on it indefinitely. Additionally, we would advise that
his family members undergo genetic testing.
Case 2
This 17-year-old African American female presented
with pain and swelling in her extremities along with
shortness of breath and palpitations. Laboratory eval-
uation revealed mild anemia, elevated erythrocyte
sedimentation rate, multiple positive autoantibodies
(anti-Ro, anti-La, Smith), and antinuclear antibodies of
1:640. She was treated with high-dose steroids for
possible systemic lupus erythematosus, and her
symptoms improved. A year later, she presented with
altered mental status, slurred speech, and shortness of
breath due to septic shock secondary to a pneumonia.
Over the next 3 days, she developed AKI, worsening
anemia, thrombocytopenia, elevated lactate dehydro-
genase, and a low haptoglobin level. A diagnosis of
thrombotic thrombocytopenic purpura/aHUS was
considered, and treatment with plasmapheresis and
eculizumab was initiated. Test results for ADAMTS13
levels came back normal. Renal biopsy demonstrated a
TMA. Genetic workup identified a missense variant
(p.I306V) in FI. She had complete renal and hematologic
recovery after 6 weeks. Eculizumab was discontinued
and she was treated with mycophenolate mofetil.
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Figure 3. Functional evaluation of Factor I (FI) variant R406H: cofactor activity. The fluid-phase C3b cofactor activity of the variant FI with its
cofactor proteins (Factor H [FH], membrane cofactor protein [MCP], or complement receptor 1 [CR1]) was assessed by cleavage of purified C3b
to iC3b and compared to wild type (WT). The percentage of alpha chain remaining and the generation of an a1 fragment indicates cleavage of
C3b to iC3b. A kinetic analysis of cofactor activity was conducted at time 0, 10, 20, and 30 minutes. Cleavage rate was measured by densi-
tometric analysis of the alpha chain remaining or the generation of a1 relative to the b chain. Representative Western blot for FH, MCP, and CR1
(a–c). Densitometric quantification of the Western blot for FH, MCP, and CR1 (d–f). Data represent 3 separate experiments with bars corre-
sponding to the SEM. Upon comparison to WT FI, the cofactor activity of variant R406H is defective with both FH and CR1. For FH, the P value for
the difference in the percentage of alpha chain remaining between WT and variant was 0.05, and for the difference in a1 generation, it was
0.0037. For CR1, the P value for the difference in the percentage of alpha chain remaining was 0.028, and for the difference in a1 generation, it
was 0.0081. No defect was observed with MCP as the cofactor protein. H, histidine; R, arginine.
RESEARCH LETTERS
Kidney International Reports (2019) 4, 1004–1018 1011
Genetic Analysis
This heterozygous variant is in the serine protease–
linker domain of FI. It occurs at an amino acid posi-
tion that is not highly conserved and has a minor allele
frequency of w0.5% within the African American
population. In silico tools predict a benign effect on
the translated protein. This particular variant has been
identified in a patient in the setting of de novo TMA
following kidney transplantation.8 On the basis of
these collective findings, the variant is categorized as a
VUS.
Antigenic Analysis
The secretion of the recombinantly produced variant
protein in the supernatant (determined by enzyme-
linked immunosorbent assay) was comparable to WT
(WT, 2.2  1.07 mg/ml; I306V, 2.7  0.5 mg/ml). The
serum FI antigenic level in our patient is not available.
However, the serum FI level in the patient previously
reported in the literature was normal: 61 mg/ml
(reference range for the outside laboratory: 42–78
mg/ml).
Functional Analysis
The variant had a normal degree of activity with all 3
cofactors (FH, MCP, and CR1) (Figure 4a). P values
for the difference in degradation of the aʹ chain of C3b
and for the generation of the a41 and a43 fragments
between WT and variant were not statistically
significant.
Structural Analysis
In the crystal structure of C3b-FH-FI, I306 is located
>30 Å and 57 Å away from the FI–C3b and FI–FH
binding interfaces, respectively. Hence, I306 is not
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Figure 4. Cofactor activity of I306V (a), P553S (b), and D403N (c), compared to wild type. Densitometric quantification of the Western blot for per-
centage of alpha chain remaining for wild type and each variant. Data represent 3 separate experiments with bars corresponding to the SEM. No
significant differences were observed. Due to the limited cleavage of C3b with D403N using membrane cofactor protein (MCP) as the cofactor, we
conducted the experiment under low ionic strength conditions (25 mM NaCl) and obtained the same results (see Supplementary Figure S1). CR1,
complement receptor 1; D, aspartic acid; FH, Factor H; I, isoleucine; N, asparagine; P, proline; S, serine; V, valine.
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involved in protein–protein interactions (Figure 2).
Furthermore, Ile to Val is a conservative mutation,
usually well tolerated by the protein fold. On these
structural bases, the I306V mutation is expected to
have no detrimental effects on cofactor activity.
Implications
This variant is of “no functional consequence” based
on normal expression and cofactor activity. Given our
current findings, in silico tools that support a benign
effect of this variant on FI, the frequency among those
with African ancestry, this variant would be reclassi-
fied as likely benign per ACMG guidelines. The patient
remains stable on mycophenolate mofetil and off anti-
complement therapy. We believe that the TMA was
most likely secondary to lupus or infection and was not
related to the variant in FI.
Case 3
This 20-year-old Caucasian female developed pre-
eclampsia during her second pregnancy and underwent
a cesarean section. The postpartum course was
complicated by the development of anemia (Coombs
negative hemolytic anemia), thrombocytopenia, and
AKI. Over the next few days, her hematologic param-
eters improved, but her kidney function did not
recover and she progressed to end-stage renal disease.
A differential diagnosis of HELLP (hemolysis, elevated
liver enzymes, low platelets) versus aHUS was consid-
ered. A year later, she was referred to us for evaluation
for a kidney transplant. In order to elucidate a more
definitive cause of the kidney failure (that is, to
determine if the patient had aHUS and pregnancy was a
likely second hit) and to further define risk of recur-
rence after transplant, genetic testing was performed.
A missense variant (p.P553S) in FI was identified.
Genetic Analysis
This heterozygous variant is in the serine protease
domain. It has been described in age-related macular
degeneration and is more common in controls than
patients (minor allele frequency of 0.2 vs. 0.06). The
variant has also been reported in a 30-year-old patient
with end-stage renal disease from aHUS9; however, that
patient carried variants in FH (p.R1210C) and in MCP
(p.Y29X; see Implications section). The variant p.P553S
is predicted to be “likely benign” by the computational
programs.
Antigenic Analysis
The secretion of the recombinant variant protein in the
supernatant (determined by enzyme-linked immuno-
sorbent assay) was comparable to WT (WT, 3.1  0.5
mg/ml; P553S, 2.1  0.28 mg/ml). The serum FI anti-
genic level in this patient was normal at 34 mg/ml
(reference range: 24–49 mg/ml).
Functional Analysis
This variant had normal activity with FH, MCP, and
CR1 serving as the cofactor protein (Figure 4b).
There was no statistically significant difference in
the cleavage of the aʹ chain or in the production
of the a1, a41, and a43 fragments, compared
with WT.
Structural Analysis
P553 is located >20 Å from the catalytic triad and is
part of the short loop exposed to the solvent. P553 is
part of neither the substrate-enzyme nor the cofactor-
enzyme binding interfaces (Figure 2).
Implications
This variant is of “no functional consequence” based
on normal expression and proteolytic activity.
Considering the findings of these studies, ACMG now
classifies this variant as benign. Although FI mutations
have been identified in patients with preeclampsia,S27
and evidence from previous experiments has shown
that dysregulation of complement activation is
involved in the development of preeclampsia, this does
not seem to be true for this patient. In the previously
reported case of aHUS with this variant, the patient
also carried the pathogenic variants, p.R1210C in FH
and p.Y29X in MCP.9 The combination of R1210C and
Y29X was likely synergistic in manifestation of disease
in the previously reported patient. In our patient,
however, it is unlikely that P553S is causative of the
renal disease.
Case 4
This 57-year-old Caucasian male presented with
generalized fatigue and weakness ongoing for 10
days. The patient was found to be in septic shock
secondary to a hepatic abscess. Three days later, he
experienced a rapid critical decline characterized by
AKI requiring dialysis, hemolytic anemia, and pro-
found thrombocytopenia. A diagnosis of thrombotic
thrombocytopenic purpura/aHUS was made, and he
was treated with plasmapheresis and eculizumab,
with complete hematologic and renal recovery over
the next 6 weeks. Test results for ADAMTS13 level
came back normal. Genetic testing revealed a rare
variant (p.D403N) in FI. He remains on eculizumab
(for the past 6 years).
Genetic Analysis
This heterozygous variant is in the serine protease
domain and is present in population databases at
very low allele frequencies (0.008% in NHLBI
Exome Variant server and 0.00003% in the ExAC
browser). In silico models predict a benign effect on
protein function. This variant was also identified in
1 of 202 patients with aHUS in a French cohort and
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was absent from 100 healthy controls.9 Based on the
limited evidence available, this variant is classified
as a VUS.
Antigenic Analysis
The secretion of the variant in the supernatant (deter-
mined by enzyme-linked immunosorbent assay) was
comparable to WT (WT, 4.8  0.55 mg/ml; D403N, 3.8
 0.97 mg/ml). Factor I antigenic level in our patient
was normal at 28.3 mg/ml (normal range: 16–40 mg/ml).
Functional Analysis
The variant had normal activity with the 3 cofactors
analyzed (Figure 4c and Supplementary Figure S1).
Compared to WT, there was no statistically significant
difference in cleavage of the aʹ chain of C3b or in the
production of the a1, a41, or a43 fragments.
Structural Analysis
D403 is located just 3 amino acids downstream of R406
(Case 1; Figure 2). Unlike R406, the side chain of D403
does not make direct contact with FH. The mutation
D403N replaces a hydroxyl with an amino group,
which retains the H-bonding capabilities. This substi-
tution is, therefore, expected to have minimal impact
on the structural properties of the loop and thus on
cofactor activity.
Implications
This variant is of “no functional consequence” based
on normal expression and proteolytic activity with all 3
cofactor proteins and a normal FI antigenic level.
Although this variant would be expected to be classi-
fied as benign, this variant remains a VUS due to its
rarity in the general population. The patient has been
stable on eculizumab for 6 years. Although categori-
zation of a variant as VUS is not recommended for use
in clinical decision-making, given these new functional
data, a trial of eculizumab may be attempted along with
close follow-up and monitoring.
Case 5
This 24-year-old Caucasian male underwent a heart
transplant at the age of 9 years for arrhythmogenic
ventricular dysplasia. He developed AKI at the age of
19 years. Laboratory values (platelet count 40,000/ml,
creatinine 1.5 mg/dl [baseline 0.9 mg/dl] and presence
of schistocytes on peripheral smear) were concerning
for aHUS, but a precipitating event was not apparent.
During the course of his hospitalization, his creatinine
level did not improve and he remained thrombocyto-
penic. Genetic testing revealed the presence of a novel
variant (p.I370N) in FI.
Genetic Analysis
This heterozygous novel missense variant is in the
serine protease domain and occurs at an amino acid
position that is highly conserved. In silico algorithms
predict this change to be deleterious to protein func-
tion. The p.I370N variant is not reported in population
variant databases. On the basis of this evidence, this
variant was characterized as “likely pathogenic.”
Antigenic Analysis
This variant was synthesized but was not secreted, as
evident from the Western blot analysis of the cell ly-
sates and the supernatants (Figure 5). The serum FI
antigenic level in this patient was not available.
Structural Analysis
Ile370 is buried into a hydrophobic pocket (Figure 2)
surrounded by I368, Y369, L376, V454, V540, F577,
and I569. Introduction of a polar amino acid such as an
asparagine is expected to disrupt the hydrophobicity of
this pocket, thereby leading to protein instability and
misfolding.
Implications
Based on these functional studies showing defective
secretion and prior supporting information, this novel
variant is reclassified as pathogenic per ACMG. The
patient is at high risk of recurrent aHUS. Of note here is
that the patient did not develop aHUS at the time of the
heart transplant, which would be considered a
precipitating event, but rather developed the disease at
a later age without a clear trigger. This patient should
Figure 5. Biosynthetic evaluation of I370N. Western blots of super-
natants and cell lysates from transfected wild type and I370N are
shown. Supernatants: the reduced blot for wild type demonstrates a
band at 50 kDa that is the heavy chain, and a band at 38 kDa that is
the light chain. The nonreduced blot shows a single band of full
length Factor I (FI) at w88 kDa. No bands are seen for I370N,
indicating that the protein either is not synthesized or not secreted.
Purified FI differs slightly in molecular weight from the recombinant
wild type (particularly under non-reducing conditions), most likely
secondary to a difference in the glycosylation (a). Lysates: the
reduced and nonreduced blots show a predominant single band at
88 kDa. This represents Pro-FI. Mutant protein is observed in the
lysate, indicating that the protein is synthesized but is not secreted,
as it is absent in the supernatants. The polyclonal antibody to FI
predominantly binds to the heavy chain at the expected molecular
weight (50 kDA) but variably detects the light chain under reducing
conditions (b). I, isoleucine; N, asparagine.
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be treated with eculizumab. Unfortunately, this patient
has been lost to follow up.
DISCUSSION
Recent technological advances in genetic testing have
enabled laboratories to expand the data obtained from
DNA analyses. However, correct functional interpre-
tation of such analyses continues to be a challenge.S28
As a result, the clinical significance of many genetic
variants remains unresolved and raises a number of
problematic questions. Should they inform clinical
management? What follow-up studies should be per-
formed? Should the data be disclosed to patients and
how should the patients be counseled? In an attempt to
help resolve such issues, the ACMG has issued guide-
lines for clinicians.5 The ACMG’s variant classification
guidelines state that “A variant of uncertain signifi-
cance should not be used in clinical decision making.
Efforts to resolve the classification of the variant as
pathogenic or benign should be undertaken through
further testing.”
Table 2. Summary of genetic and functional analyses of Factor I variants in aHUS
Variant dbSNP ID g. syntax Domain
Serum
levels Recombinant secretion
CA
(FH)
CA
(MCP)
CA
(CR1)
Previous ACMG
interpretation
Modified ACMG
interpretation
R406H rs74817407 chr4:
g.110667590C>T
SP NL NL DF NL DF LB VUS
I306V rs113273712 chr4:
g.110673648T>C
LNK NAa NL NL NL NL VUS LB
P553S rs113460688 chr4:
g.110662144G>A
SP NL NL NL NL NL LB Benign
D403N rs139881195 chr4:
g.110667600C>T
SP NL NL NL NL NL VUS VUS
I370N novel chr4:
g.110670413A>T
SP NA Protein synthesized; not
secreted
ND ND ND LP Pathogenic
ACMG, American College of Medical Genetics; aHUS, atypical hemolytic uremic syndrome; CA, cofactor activity; CR1, complement receptor 1; dbSNP, database of single-nucleotide
polymorphisms; DF, defective; FH, Factor H; LB, likely benign; LNK, linker; LP, likely pathogenic; MCP, membrane cofactor protein; NA, not available; ND, not done; NL, normal; SP, serine
protease; VUS, variant of uncertain significance.
aNormal in the one other case reported in Le Quintrec et al.8
•
•
Medical history/physical examination
Labs (thrombocytopenia, microangiopathic hemolytic anemia, 
+ one or more of the following:
Renal failure/neurological symptoms/gastrointestinal symptoms)
Evaluate ADAMTS13 activity/STEC-toxin
(C3, C4, CH50)
≤5% ADAMTS 13 activity >5% ADAMTS 13 activity STEC toxin positive
aHUS
STEC-HUS
Antigenic levels
(FH, FI, FB, C3); MCP expression using flow cytometry; 
Anti-FH AutoAb level; C3Nef level 
Genetic testing
(FH, FI, FB, MCP, C3)
Variant identified Abnormal
(aHUS)
Normal 
In silico prediction models
Known mutation Novel variant or known variant but 
never studied 
Prepare mutant in lab to study functionPathogenic
(aHUS)
TTP
Benign
Functional assays
(FH, FI, MCP)
Low
(aHUS)
Combine clinical, genetic, functional, and structural data to define variant
Figure 6. Diagnostic algorithm for atypical hemolytic uremic syndrome (aHUS). ab, antibody; ADAMTS13, a disintegrin and metalloproteinase
with a thrombospondin type 1 motif, member 13; C3Nef, C3 nephritic factor; FB, Factor B; FH, Factor H; FI, Factor I; MCP, membrane cofactor
protein; STEC, Shiga toxin–producing Escherichia coli; TTP, thrombotic thrombocytopenic purpura.
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One way to further address this issue is to test family
members to determine whether variants are shared by
other affected and unaffected relatives. In our cases,
the family histories were negative for a similar syn-
drome. Also, even if suggestive, this approach can be
time consuming and labor intensive, and it relies on
family availability, cooperation, and consent. Addi-
tionally, insurance companies refuse to pay for this
testing. Another approach is to model the genetic
variant using mutagenesis, protein expression, and
structure–function analyses to more definitively iden-
tify the clinical implications of each genetic variant.
Consequently, we performed analyses of the 5 var-
iants in FI identified in aHUS (2 were VUS; 2 were
likely benign; and 1 was likely pathogenic). Using
these “real-world” cases, we obtained functional and
structural data on each variant. The results were utilized
to reclassify the variants per the ACMG guidelines
(Table 2).8 They changed the clinical interpretation for 4
of the 5 variants.
Putative limitations to our analyses are as follows: (i)
Incomplete penetrance of a variant can confound the
standard ACMG guideline interpretation. For example,
despite our functional data demonstrating no func-
tional defect, the interpretation for p.D403N remained a
VUS due to the rarity of the variant. Investigating the
effect of this variant on the cell surface might be
additionally instructive. (ii) Assays could also incor-
porate the cofactor for C4b cleavage, i.e., C4b-binding
protein. However, rather than the classical pathway,
it is the alternative pathway that mediates aHUS. (iii)
The relative levels of the fully functional form of FI
versus the level of the rare variant are unknown. (iv)
Longer-term follow-up is needed to assess the outcome
of the clinical course for each patient. (v) Given that
these functional studies were not conducted in a Col-
lege of American Pathologists (CAP)–accredited and
Clinical Laboratory Improvement Amendments (CLIA)–
certified laboratory, routine use of these methods to
facilitate clinical decision-making will require sub-
stantial investment in developing high-throughput
assays.
Nevertheless, our results identify a useful model
(Figure 6) illustrating how a sequential and systematic
analysis can provide more accurate investigation of the
clinicopathologic significance of genetic variants in
aHUS. Additional studies of complement parameters,
including, for example, activation fragments, could add
important information to inform therapeutic decisions.
Such a model provides a means to further define an
individualized treatment plan as well as the risk of
recurrence after a kidney transplant.
In conclusion, given the current challenges to the
clinician of reconciling genetic data with clinical
management of aHUS, we believe our strategy of re-
combinant protein production followed by detailed
functional and structural assessments is informative.
The ability to more comprehensively define the func-
tional repertoire of the variant protein provides critical
guidance relative to the appropriate therapeutic
regimen and thereby will ultimately pave the way for
precision medicine in complement-mediated renal
disease.
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M easurement of retinol-binding protein 4 (RBP4) inurine plays an important role as a sensitive func-
tional biomarker of proximal renal tubular disease, a diag-
nostic feature of renal Fanconi syndrome.1,2 The syndrome
may be hereditary, as in Dent 1 or Dent 2 diseases and
manyother syndromes, or acquired, as in several drug tox-
icities targeting the proximal tubule.2,3 The “free” form of
RBP4 in plasma (molecular weight: 21 kDa) comprises
about 14% of total RBP4, the remainder being complexed
to the carrier protein, transthyretin, as RBP4–transthyre-
tin, with a molecular weight of 76 kDa.4 The literature
generally refers to the “free” form of plasma RBP4 as being
freely filtered by the renal glomerulus, in much the same
way as b2-microglobulin, with a molecular weight of
11.6 kDa.2,5 b2-microglobulin has an estimated
glomerular-sieving coefficient (GSC) of 0.94  0.1 and
0.97, as measured directly in animal studies,6,7 and 0.91
 0.14 from indirect measurement in humans.8 Curiously,
the GSC of RBP4 has not been measured in animals, and
there is only one indirect measurement in humans.8
A new, sensitive, and accurate assay for the free
form of RBP4 in urine (UfRBP) has recently been
developed, and we have used it to reexamine the GSC
of fRBP4.9 The approach we use is similar to that
previously reported, but it has yielded markedly
different results based on the new and more accurate
measurement of UfRBP4. Patients with Dent 1 disease,
due to a CLCN5 mutation, were studied. In these pa-
tients, there appears to be a “knockout” of reabsorp-
tion of proteins by the proximal renal tubule, and this
is supported by experimental work.S1–S4 This reab-
sorption normally relies on the function of CLC5, the
gene product of CLCN5, which is required for megalin/
cubilin-dependent receptor-mediated endocytosis. As a
result, assuming a complete knockout and absence of
other pathways for addition or loss of protein, the
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